Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05406024
Other study ID # 2021_0215
Secondary ID 2021-A02644-37
Status Not yet recruiting
Phase
First received
Last updated
Start date September 2022
Est. completion date September 2023

Study information

Verified date March 2022
Source University Hospital, Lille
Contact Guillaume Piessen, MD,PhD
Phone 0320445962
Email guillaume.piessen@chru-lille.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The incidence of cancer in France has increased by +135% to reach nearly 400,000 new cases in 2018. The ten-year cancer control strategy 2021-2030 and the health innovation plan have defined strategic axes. Almost all of these axes are addressed in our project. Firstly, the main objective of our study is to improve the quality of life of patients. Secondly, pharyngolaryngeal and oesophageal cancers are among the cancers with a poor prognosis in adults. Thirdly, the project provides access to personalised supportive care for all patients at all times. Finally, the secondary objectives of this study are the prevention of post-operative complications (infectious, thrombo-embolic, pain...).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date September 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hospitalized for initial surgical management of esophageal or laryngeal cancer - Admitted to a conventional ward after partial oesophagectomy or total laryngectomy in a neoplastic setting - Patient giving consent to participate in the study - Affiliated to the compulsory health insurance scheme, regardless of the scheme Exclusion Criteria: - Patient who did not follow the previously described course of care prior to admission to the ward - Esophagectomy with total circular pharyngo-laryngectomy - Total esogastrectomy - Illiterate, visually impaired patient - Minor, or adult under guardianship or curatorship, under judicial protection, person deprived of liberty

Study Design


Intervention

Device:
Digital platform
The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Lille ENGIE, Fondation Boulanger, Santelys Association

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability rate Realization of the ratio between the number of inclusion proposals and the number of accepted inclusions. At 1 year
Secondary Adherence to exercise intervention program: Number of login Discharge from hospital if it occurs before 30 days or at Day 30
Secondary Adherence to exercise intervention program: Number of exercises completed Discharge from hospital if it occurs before 30 days or at Day 30
Secondary Adherence to exercise intervention program: type of exercises completed Discharge from hospital if it occurs before 30 days or at Day 30
Secondary Adherence to exercise intervention program: retention rate Discharge from hospital if it occurs before 30 days or at Day 30
Secondary Satisfaction by the System Usability Scale Discharge from hospital if it occurs before 30 days or at Day 30
Secondary Classification de Clavien-Dindo Evaluation of the incidence of postoperative complications based on the Clavien-Dindo classification grade II At day 30
Secondary Visual Analogue Scale Measure the pain in the scale from 0 to 10 Before and after each activity
Secondary Instant Well-Being Evaluation (IWBE) It consists of a graduated scale: the patient must position a cursor, the position on the left corresponding to "I feel very well" and the position on the right to "I do not feel well". The patient is guided by a pictogram (happy, neutral or sad face) Baseline, Discharge from hospital if it occurs before 30 days and at Day 30
Secondary Warwick-Edinburgh Mental Wellbeing Scales The well-being and theu quality of life will be assessed using the Warwick-Edinburgh Mental Wellbeing Scales Each item is scored on a range from 1 to 5. The total score will be between 14 and 70, with lower scores indicating poor wellbeing, and higher scores indicating greater wellbeing. Very low wellbeing is defined as a score of = 45. A substantial decrease in wellbeing is a decrease by 5 or more points. Baseline, Discharge from hospital if it occurs before 30 days and at Day 30
Secondary EuroQuol 5 Dimensions (EQ-5D-5L) The quality of life will be assessed using the EuroQuol 5 Dimensions The EQ-5D-5L questionnaire will be used to estimate the impact on subjects' health-related quality of life and provides a description of subjects' problems by dimensions (descriptive system), a score for overall self-rated health (visual analogue scale [VAS]) as well as an index score (EQ-5D-5L index). EQ-5D index score range: 0 to 1 and EQ-5D-VAS: range 0 to 100. A higher score indicates better self reported health status. Baseline, Discharge from hospital if it occurs before 30 days and at Day 30
Secondary European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30) The quality of life will be assessed using the EORTC-QLQ-C30 The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many clinical trials in oncology Baseline, Discharge from hospital if it occurs before 30 days and at Day 30
See also
  Status Clinical Trial Phase
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Terminated NCT02601079 - Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis N/A
Active, not recruiting NCT01745107 - Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Phase 3
Active, not recruiting NCT02969473 - Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT00288119 - Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Terminated NCT01870791 - Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer Phase 2
Active, not recruiting NCT00431756 - Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Not yet recruiting NCT05736705 - Monopolar and Bipolar in Esophageal ESD N/A
Completed NCT02395705 - Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Phase 3
Completed NCT02033213 - Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial N/A
Terminated NCT00653107 - Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only Phase 3
Completed NCT01927016 - Outcomes After Esophageal Cancer Surgery N/A
Completed NCT02558504 - Radiofrequency in the Treatment of Barrett's Oesophagus Phase 4
Active, not recruiting NCT02636088 - Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer Phase 2
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Completed NCT00318903 - Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Phase 2
Recruiting NCT02583087 - ESD for the Treatment of Early Barrett's Neoplasia N/A
Active, not recruiting NCT04489368 - Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning